VC  Valence Life Sciences

http://www.valencefund.com





     Office Locations:

590 Madison Avenue 21st floor
New York, NY 10022
Phone: 212-521-4379
Fax: 212-692-6072

 

Stages:

  • Expansion


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Valence Life Sciences is a leading life sciences investment firm focused on late-stage private and micro-cap public drug development companies. Valence Advantage Life Sciences Fund II was established in 2012 by Managing Directors, Eric W. Roberts and A. Rachel Leheny, Ph.D.-- one of Wall Street's premier life sciences investment banking and research teams. Fund II is the successor to Caxton Advantage Life Sciences Fund I which Mr. Roberts and Dr. Leheny began investing in 2006 with the same investment strategy. Valence Advantage Life Sciences was formed as an entity independent of an affiliate of Caxton Associates, a New York-based trading and investment firm. Dr. Leheny, Mr. Roberts and their team will continue to manage Caxton Advantage's nine portfolio companies.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    A. Rachel Leheny Ph.D. Managing Director
    Eric W. Roberts Managing Director
    Jay Cecil Managing Director
    Rob Ferraioli Vice President & Controller
    Scott Morenstein Managing Director

     

    Portfolio companies include:


      Anthera
        web link


      Celator Pharmaceuticals
        web link


      Corthera
        web link


      Gentium
        web link


      Invuity
        web link


      RegadoBiosciences
        web link


      Sunesis
        web link


      Vivus
        web link


     

    Recent News: